Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement.

Publication ,  Journal Article
Lenihan, D; Carver, J; Porter, C; Liu, JE; Dent, S; Thavendiranathan, P; Mitchell, JD; Nohria, A; Fradley, MG; Pusic, I; Stockerl-Goldstein, K ...
Published in: CA Cancer J Clin
November 2020

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has given rise to a pandemic of unprecedented proportions in the modern era because of its highly contagious nature and impact on human health and society: coronavirus disease 2019 (COVID-19). Patients with cardiovascular (CV) risk factors and established CV disease (CVD) are among those initially identified at the highest risk for serious complications, including death. Subsequent studies have pointed out that patients with cancer are also at high risk for a critical disease course. Therefore, the most vulnerable patients are seemingly those with both cancer and CVD, and a careful, unified approach in the evaluation and management of this patient population is especially needed in times of the COVID-19 pandemic. This review provides an overview of the unique implications of the viral outbreak for the field of cardio-oncology and outlines key modifications in the approach to this ever-increasing patient population. These modifications include a shift toward greater utilization of cardiac biomarkers and a more focused CV imaging approach in the broader context of modifications to typical practice pathways. The goal of this strategic adjustment is to minimize the risk of SARS-CoV-2 infection (or other future viral outbreaks) while not becoming negligent of CVD and its important impact on the overall outcomes of patients who are being treated for cancer.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

CA Cancer J Clin

DOI

EISSN

1542-4863

Publication Date

November 2020

Volume

70

Issue

6

Start / End Page

480 / 504

Location

United States

Related Subject Headings

  • Trastuzumab
  • SARS-CoV-2
  • Referral and Consultation
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Radiotherapy
  • Protein Kinase Inhibitors
  • Proteasome Inhibitors
  • Oncology & Carcinogenesis
  • Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lenihan, D., Carver, J., Porter, C., Liu, J. E., Dent, S., Thavendiranathan, P., … Herrmann, J. (2020). Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. CA Cancer J Clin, 70(6), 480–504. https://doi.org/10.3322/caac.21635
Lenihan, Daniel, Joseph Carver, Charles Porter, Jennifer E. Liu, Susan Dent, Paaladinesh Thavendiranathan, Joshua D. Mitchell, et al. “Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement.CA Cancer J Clin 70, no. 6 (November 2020): 480–504. https://doi.org/10.3322/caac.21635.
Lenihan D, Carver J, Porter C, Liu JE, Dent S, Thavendiranathan P, et al. Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. CA Cancer J Clin. 2020 Nov;70(6):480–504.
Lenihan, Daniel, et al. “Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement.CA Cancer J Clin, vol. 70, no. 6, Nov. 2020, pp. 480–504. Pubmed, doi:10.3322/caac.21635.
Lenihan D, Carver J, Porter C, Liu JE, Dent S, Thavendiranathan P, Mitchell JD, Nohria A, Fradley MG, Pusic I, Stockerl-Goldstein K, Blaes A, Lyon AR, Ganatra S, López-Fernández T, O’Quinn R, Minotti G, Szmit S, Cardinale D, Alvarez-Cardona J, Curigliano G, Neilan TG, Herrmann J. Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. CA Cancer J Clin. 2020 Nov;70(6):480–504.
Journal cover image

Published In

CA Cancer J Clin

DOI

EISSN

1542-4863

Publication Date

November 2020

Volume

70

Issue

6

Start / End Page

480 / 504

Location

United States

Related Subject Headings

  • Trastuzumab
  • SARS-CoV-2
  • Referral and Consultation
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Radiotherapy
  • Protein Kinase Inhibitors
  • Proteasome Inhibitors
  • Oncology & Carcinogenesis
  • Neoplasms